Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | May 01, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.82 · Expires 2036-05-01 | Direct | 48,800 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 48,800 · Balance 48,800 F1: The options were granted pursuant to the Company's non-employee director compensation policy. F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the Company's non-employee director compensation policy.
F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 1, 2026 20:08 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001409939-26-000004 · form4-05012026_080538.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2036-05-01 F1 · security: The options were granted pursuant to the Company's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| April 06, 2026 Filed Apr 6, 2026 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 9,200 | $3.41 | $31,349.92 |
DisclosureSEC source: 0001409939-26-000002 · form4-04062026_040403.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,700 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4050 to $3.4080, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 23, 2025 Filed Dec 23, 2025 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 12,500 | $4.10 | $51,250.00 |
DisclosureSEC source: 0001409939-25-000005 · form4-12232025_041201.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 20:17 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001104659-25-094493 · tm2527377-5_4seq1.xml · derivative · entry 2 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2035-09-25 F3 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 26, 2024 Filed Sep 30, 2024 22:34 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 34,900 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001104659-24-104439 · tm2425266d3_4.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,900 Underlying: Common Stock, par value $0.0001 · 34,900 shares Expires 2034-09-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 26, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 26,100 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001104659-23-105393 · tm2327241-4_4seq1.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock, par value $0.0001 · 26,100 shares Expires 2033-09-28 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 29, 2022 Filed Oct 1, 2022 01:21 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 23,500 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001104659-22-104778 · tm2227177-4_4seq1.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock, par value $0.0001 · 23,500 shares Expires 2032-09-29 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 29, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| August 12, 2022 Filed Jul 6, 2023 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 2,714 | $15.00 | $40,710.00 |
DisclosureSEC source: 0001104659-23-078839 · tm2320770-1_4seq1.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,771 F1 · shares: Pursuant to that certain Form 5 filed on February 14, 2022, the Reporting Person gifted these 2,714 shares of common stock on December 27, 2021 to an immediate family member. Read SEC document |
| January 06, 2022 Filed Sep 29, 2025 20:17 UTC | Altimmune, Inc. ALT · Entity 5349 | GiftCommon Stock, par value $0.0001 | 2,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-094493 · tm2527377-5_4seq1.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents a bona fide gift of 2,714 shares of common stock made on January 6, 2022. F2 · balance_after: Certain Section 16 reports previously filed by the reporting person inadvertently overstated the reporting person's direct common stock ownership by 57 shares. As of the date of this filing, the reporting person does not hold any shares of common stock directly or indirectly. Read SEC document |
| December 27, 2021 Filed Feb 14, 2022 22:01 UTC | Altimmune, Inc. ALT · Entity 5349 | GiftCommon Stock, par value $0.0001 | 2,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023082 · tm226690d1_5.xml · nonDerivative · entry 3 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 F2 · kind: This transaction was a bona fide gift of common stock made on December 27, 2021. F2 · shares: This transaction was a bona fide gift of common stock made on December 27, 2021. Read SEC document |
| December 27, 2021 Filed Feb 14, 2022 22:01 UTC | Altimmune, Inc. ALT · Entity 5349 | GiftCommon Stock, par value $0.0001 | 2,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023082 · tm226690d1_5.xml · nonDerivative · entry 2 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,485 F2 · kind: This transaction was a bona fide gift of common stock made on December 27, 2021. F2 · shares: This transaction was a bona fide gift of common stock made on December 27, 2021. Read SEC document |
| September 23, 2021 Filed Sep 25, 2021 00:45 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 24,100 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001104659-21-119483 · tm2128463-2_4seq1.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,100 Underlying: Common Stock, par value $0.0001 · 24,100 shares Expires 2031-09-23 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 23, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 03, 2021 Filed Feb 14, 2022 22:01 UTC | Altimmune, Inc. ALT · Entity 5349 | GiftCommon Stock, par value $0.0001 | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023082 · tm226690d1_5.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,199 F1 · kind: This transaction was a bona fide gift of common stock made on May 3, 2021. F1 · shares: This transaction was a bona fide gift of common stock made on May 3, 2021. Read SEC document |
| November 30, 2020 Filed Dec 3, 2020 00:05 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 8,425 | $11.92 | $100,426.00 |
DisclosureSEC source: 0000899243-20-032575 · doc4.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,199 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 22:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 25,500 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0000899243-20-026409 · doc4.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock, par value $0.0001 · 25,500 shares Expires 2030-09-24 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 24, 2020, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| September 24, 2020 Filed Oct 16, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units ("RSUs") · Derivative | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028539 · doc4.xml · derivative · entry 2 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F2 · derivative.exercise_date: On June 25, 2020, the reporting person was granted 16,850 restricted stock units, which vested in full at the Company's 2020 annual meeting of stockholders on September 24, 2020. F2 · derivative.expiration_date: On June 25, 2020, the reporting person was granted 16,850 restricted stock units, which vested in full at the Company's 2020 annual meeting of stockholders on September 24, 2020. Read SEC document |
| September 24, 2020 Filed Oct 16, 2020 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028539 · doc4.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:50 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units ("RSUs") · Derivative | 16,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017826 · doc4.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,850 Underlying: Common Stock · 16,850 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F2 · derivative.exercise_date: The RSUs vest in full at the Company's 2020 annual meeting of stockholders, subject to the reporting person's continued service through the vesting date, and have no expiration date. F2 · derivative.expiration_date: The RSUs vest in full at the Company's 2020 annual meeting of stockholders, subject to the reporting person's continued service through the vesting date, and have no expiration date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:11 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001012975-19-000035 · edgar.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: The option becomes vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| October 13, 2017 Filed Oct 18, 2017 00:12 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001012975-17-000764 · edgar.xml · derivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2027-10-13 Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 20:49 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 1,000 | $4.34 | $4,343.50 |
DisclosureSEC source: 0001012975-17-000474 · edgar.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,224 Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001144204-16-136389 · v453827_4.xml · derivative · entry 2 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 21:47 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, $0.0001 par value per share | 100,000 | $2.20 | $220,000.00 |
DisclosureSEC source: 0001144204-16-136389 · v453827_4.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · derivative · entry 12 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2019-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · derivative · entry 11 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 per share | 20,000 | $2.47 | $49,400.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · nonDerivative · entry 6 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 per share | 10,000 | $2.59 | $25,900.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · nonDerivative · entry 5 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · derivative · entry 10 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · derivative · entry 9 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · derivative · entry 8 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · derivative · entry 7 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2020-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 per share | 20,000 | $1.51 | $30,200.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · nonDerivative · entry 4 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 per share | 20,000 | $1.64 | $32,800.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · nonDerivative · entry 3 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 per share | 20,000 | $1.45 | $29,000.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · nonDerivative · entry 2 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 22:00 UTC | Altimmune, Inc. PIP · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 per share | 20,000 | $1.60 | $32,000.00 |
DisclosureSEC source: 0001144204-16-124460 · v449040_4.xml · nonDerivative · entry 1 GILL JOHN · CIK 0001409939 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.